With Gamifant launch rolling, Sobi unveils more data backing the rare disease med
SAN DIEGO—Armed with last month’s FDA approval, Sobi is rolling out its newly minted rare disease drug Gamifant with a small, targeted sales force, and Monday it unveiled more of the data that won the agency’s favor in the first place. In a phase 2/3 trial of Gamifant in primary haemophagocytic lymphohistiocytosis (HLH), 64.7% of… Read More: With Gamifant launch rolling, Sobi unveils more data backing the… »